However, imatinib/Gleevec, an FDA-approved antileukemia drug and PDGFRβ inhibitor, is known to cause multiple adverse drug reactions, including thrombocytopenia.39 Systemic inhibition of PDGFRβ with cytotoxic anti-PDGFRβ drugs may be risky. This evidence concerns the gene PDGFRB and Thrombocytopenia.